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The development of human T  cell hybridomas secreting immunoregulatory mole- 
cules has been an area of recent intense interest and investigation. Functional hybrids 
derived from both normal and malignant human T  cells have been developed. These 
hybrids have been demonstrated to secrete interleukin 2 (IL-2)  1 (1), killer helper factor 
(2), and factors that help or suppress immunoglobulin production (3, 4). Application 
of the hybridization technique of Kohler and Milstein  (5)  to murine T  lymphocytes 
has yielded an even wider variety of factors with immunoregulatory function (6-9). 
Factors produced by T  cell hybrids have proven to be valuable as a source of purified 
immunoregulatory molecules for use in immunochemical as well as functional studies. 
Recent  studies  (10-12)  have  demonstrated  that  exogenous  growth  factors  are 
necessary to  support  proliferation  of normal  murine  and  human  B  cells  placed  in 
long-term  culture.  In  the  past,  mitogen  stimulation  of human  peripheral  blood 
lymphocytes (PBL) has been used to produce supernatants with B cell growth factor 
(BCGF) activity (i0). These conventionally generated supernatants are heterogeneous 
in composition, vary significantly in their ability to support B cell proliferation, and 
often contain growth factors for T  cells as well as for B cells  (13). In the present study, 
we  report  the  development  of a  human  T  cell  hybridoma secreting  BCGF  in  the 
absence of IL-2. 
Materials and Methods 
Lymphocyte  Preparation  and  Stimulation.  Fresh,  unfractionated  PBL obtained  from  normal 
human subjects were separated  by gradient  centrifugation  over Ficoll-Hypaque  (Pharmacia 
Fine Chemicals, Div. of Pharmacia,  Inc., Piscataway, N  J). T  lymphocytes were separated  by 
rosette formation  with aminoethylisothiouronium  bromide (AET)-treated  sheep erythrocytes 
(14), followed by passage through a nylon wool column (15). The T cell-enriched population 
was suspended  at  2 X  10  s cells/ml  in complete  media  (CM) consisting of RPMI  1640 plus 
glutamine  (Flow Laboratories,  Inc., Rockville, MD); 2/~g/ml amphotericin  B (E.  R.  Squibb 
& Sons, Inc.,  Princeton,  N  J),  140/~g/ml  gentamicin  (Schering Corp.,  Kenilworth,  N  J), and 
30% heat-inactivated  fetal calf serum (FCS) (Gibco Laboratories, Grand Island Biological Co., 
Grand Island, NY) screened to support  the growth of T cell hybrids. T cells were stimulated 
with  10 btg/ml concanavalin  A (Con A) (Sigma Chemical  Co., St. Louis, MO)  for 24 h in 24- 
well culture plates (3524; Costar, Data Packaging, Cambridge,  MA) before hybridization. 
B lymphocytes  for use in the BCGF assay (described below) were prepared  from  normal 
1 Abbreviations used in this paper:  AET,  aminoethylisothiouronium  bromide; BCGF, B cell growth factor; 
CM, complete media; Con A, concanavalin A; FCS, fetal calf serum; HAT, hypoxanthine/aminopterin/ 
thymidine; IL-2, interleukin 2; PBL, peripheral blood lymphocyte. 
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human PBL. T  cells were depleted by twice rosetting with AET-treated sheep erythrocytes, 
followed  by treatment with anti-Leu 1 antibody (Becton, Dickinson & Co., Sunnyvale, CA) 
and rabbit complement. Depletion of monocytes was performed by adhering 50 ×  10  e T  cell- 
depleted cells to plastic flasks (25116; Corning Glass Works, Corning, NY') containing RPMI 
1640 with 1% FCS for 45 min at 37°C. 
Cell Fusion Procedure.  Human T  cell hybridomas were produced by modification of fusion 
methods previously described (16-18). An azaguanine-resistant mutant of human T  lympho- 
blastoid origin (CEM-6) was used for hybridization. This variant line, kindly provided by Dr. 
J.  Stobo,  University of  California,  San  Francisco,  CA,  was  grown  continuously in  CM 
containing 15% FCS and harvested at the mid-logarithmic ~hase of growth. 30 million Con A- 
activated peripheral blood T cells were mixed with 1.5 ×  10  mutant CEM-6 cells and pelleted 
by centrifugation. The cell pellet was gently resuspended in 0.5 ml of a 50% polyethylene  glycol- 
I500 solution. The cells were kept  in suspension by gently stirring at 37°C for 5  rain. The 
solution was then diluted to 10 ml by the addition of warm (37°C) RPMI 1640. The cells were 
centrifuged at 350 g for 5 min and resu_s~ended in CM containing 1 ×  10  -4 M hypoxanthine, 
4 ×  10-  M aminopterin, and 1.6 ×  10-  M thymidine (HAT; all from Sigma Chemical Co.). 
Cells were cultured in 96-well flat-bottomed microtiter plates (Costar 3596) at a concentration 
of 105 mutant cells/well in 0.2 ml. The cultures were kept at 37°C in a 7% COz incubator, and 
the culture media was replaced with fresh  HAT media every 3 d. Cloning of selected hybrid 
cells was done by the method of limiting dilution. 
Assay  for BCGFActivity.  Assay for the effect of hybridoma supernatants  on B cell proliferation 
was performed as previously described (19). In brief, the B cell-enriched population described 
above was suspended in CM containing 10% FCS and Staphylococcus aureus-Cowan strain I at a 
concentration of 5 ×  10  -4 vol/vol. 0.2-ml aliquots of the B cell-enriched fraction were added to 
the wells of a  96-well round-bottomed microtiter plate (Costar 3799) at a density of 2 ×  105 
cells/well. Cultures were maintained at 37°C in air with 7% CO2 and 100% humidity. On day 
3  of culture, 0.1  ml  of media was  removed  from  each  well  and  replaced  with  0.1  ml  of 
hybridoma supernatant. Supernatant from the unfused CEM-6 line was used as a control. 48 
h later, 1/~Ci of [3H]thymidine (New England Nuclear, Boston, MA) was added to the cultures, 
which were then continued for an additional 16 h. Cells were harvested using a Titertek cell 
harvester  (Flow Laboratories,  Inc.).  The  filter disks  were  placed  in scintillation vials and 
counted in a liquid scintillation  counter (LS-350; Beckman Instruments, Inc., Spinco Div., Palo 
Alto, CA). 
Assay for IL-2 Activity.  Supernatants from  the  T  cell  hybridomas were  assayed  for IL-2 
activity in a system previously described in detail (20). Incorporation of [3H]thymidine by an 
IL-2-dependent cytotoxic T  cell  line (CT6)  was  used  as  the  index of IL-2 activity in the 
superuatants. 
Gel Filtration.  200 ml of 2Bll supernatant was concentrated to  10 ml by Amicon filtration 
using a  YM10  membrane  (Amicon Corporation  Scientific Division, Danvers,  MA).  The 
concentrated hybridoma supernatant was next applied to a Sephadex G o  100 (Pharmacia Fine 
Chemicals) gel filtration column (90 ×  2 cm). The column was eluted with phosphate-buffered 
saline (HEM Research, Inc., Rockville, MD) at a flow rate of 12 ml/h. 2.5-ml fractions were 
collected,  and BCGF activity was assayed.  Absorbance was recorded at 280 nm. 
Results 
Development and Cloning of Hybridomas.  On the day of fusion, 768 wells were seeded 
with cells  (Table I).  The first  hybrid cells were seen  18  d  after hybridizdtion. On 
initial screening, supernatants from three wells were found to have BCGF activity. 
The cells from the positive wells were expanded and subsequently cloned at  10 cells/ 
well. Cloning efficiency was low (6%)  at this cell density. One well with rapid growth 
characteristics  (2Bll)  showed  marked enhancement of B  cell proliferation and was 
chosen for further cloning. Cloning efficiency increased to 55% when plates containing 
0.5 cells/well were assayed for BCGF activity. 
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TABLE  I 
Development and Screening of Human T Cell Hybridomas 
Number 
Days after  Number of wells cultured  of wells  Cloning 
fusion  producing  efficiency* 
BCGF 
0 
i8 
41 
47 
62 
69 
88 
(%) 
768  --  -- 
Hybrids first identified in 12 of 768 wells  --  -- 
184 Wells with hybrids screened  3  -- 
3 Positive wells cloned, 10 cells/well (288 wells)  --  -- 
230 wells screened  17  6 
Well 2Bll recloned, 0.5 cells/well (120 wells)  --  -- 
37 wells  screened  26  55 
* Calculated as number of positive wells per number of wells calculated to have 21 cells/ 
well. 
supernatants  on  B  cell proliferation, normal  human  peripheral  blood  B  cells were 
activated in culture with S.  aureus-Cowan  strain I.  On  day 3  of culture,  hybridoma 
supernatants were added, and the incorporation of tritiated thymidine was measured 
on  day  6.  As  shown  in  Fig.  1,  two  separate  T  cell  hybridoma  supernatants  had 
variable effects on the proliferative response of human B cells. Supernatant from clone 
2Bll significantly enhanced  B  cell proliferation as compared with  the response seen 
with conventional BCGF derived from phytohemagglutinin-stimulated human  PBL. 
Intermediate  BCGF  activity was  demonstrated  in  the  supernatant  from  clone  2F6. 
The  magnitude  of enhancement  of the  proliferative response  varied among  experi- 
ments; however, supernatants from clone 2Bn significantly enhanced proliferation in 
every experiment. This variability suggests that the results seen in these experiments 
were greatly influenced by the responsiveness of the B  cell populations used. Hybrid 
cells from clone 2Bn were stimulated with Con A  to investigate the effect of mitogen 
stimulation on the hybrid cell's ability to secrete a  supernatant  that enhanced B  cell 
proliferation. Mitogenic stimulation of the hybrid cells produced no significant change 
in the levels of proliferation measured  (data not shown). 
The maximum B  cell proliferative response in the assay system was dependent on 
the concentration of T  cell hybridoma supernatant added to the culture wells (Fig. 2, 
panel A). At an eightfold dilution, BCGF activity in the supernatants from clone 2Bn 
remained  high.  Thereafter,  activity  declined  with  subsequent  dilutions,  and  no 
enhancement of B cell proliferation was demonstrable at a  1:128 dilution. In contrast, 
the activity of conventionally prepared BCGF diminished at a  much more rapid rate 
so that  no  BCGF  activity was  evident  at  a  1:16  dilution. A  question  that  emerged 
from these data was whether the T-T hybridoma supernatant could maintain growth 
in  long-term  cultures  of human  B  cells.  Simultaneous  cultures  of normal  human 
peripheral  blood  B  cells  were  prepared  and  maintained  by  either  conventionally 
derived BCGF or supernatant  from clone 2Bll. Although those B  cells supplemented 
with conventional growth factor showed slow inconsistent rates of proliferation, the B 
cell  cultures  supplemented  with  clone  2Bu  supernatant  have  been  maintained  in 
culture  for  >6  wk.  Some  of  these  long-term  culture  wells  were  tested  for  their 
dependence on the 2Bn supernatant by being fed with conventional BCGF or media 
containing  no  growth  factors.  Shortly after  2Bn  was  withdrawn,  proliferation of B j.  L.  BUTLER, A.  MURAGUCHI,  H.  C.  LANE, AND A.  S.  FAUCI 
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FIe.  1.  Enhancement of human B cell proliferation by human T-T hybridoma supernatants. B 
cells (2 ×  l0  s cells/well) that  had been activated by S.  aureus-Cowan  strain I for 3 d were then 
cultured with 0.1 ml ofsupernatant derived from the CEM-6 cell line (control),  phytohemagglutinin- 
stimulated human PBL (standard BCGF), or human T-T hybridomas. Proliferation was measured 
after an additional 3 d in culture. Data represent the mean (± SEM) of triplicate experiments. 
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cells in the culture wells fed with conventional BCGF declined significantly. B  cells 
maintained in media containing no growth  factors  failed  to  proliferate and subse- 
quently died. Of note is the fact that the clone 2Bu has remained stable in culture for 
>3 rno with no diminution of BCGF activity in the supernatant. Karyotypic analysis 
of the hybridoma cells revealed a  chromosomal number of 48-50.  In contrast,  the 
normal human T  cells as  well as  the CEM-6  leukemic cells were  found to  have a 
diploid number of chromosomes. 
Supernatants from clone 2Bll were tested for IL-2 activity in an assay system using 
an IL-2-dependent T  cell line (CT6). As shown in Fig. 2, panel B, serial dilutions of 
2Bal supernatant failed to support proliferation of the CT6 cells. On the other hand, 
significant incorporation of [3H]thymidine by the cells was produced by the addition 
of a  standard IL-2 preparation. These results demonstrate no detectable contamina- 
tion of BCGF with IL-2 activity. Clone 2Bxl was also tested for its ability to induce B 
cell differentiation and antibody production in addition to proliferation. In an assay 
system using an Epstein-Barr virus-transformed B  cell  line (CESS),  no evidence of 
differentiation was demonstrated (data not shown). 64  B  CELL  GROWTH  FACTOR  SECRETING  HUMAN  T-T  CELL  HYBRIDOMA 
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DILUTION OF SUPERNATANTS 
Fro.  2.  (A)  Relationship  between  the  dilution  of T-T  hybridoma supernatant  or conventional 
growth factor and  the  degree of B cell  proliferation.  Culture conditions in this experiment were 
identical to those described in Fig.  1. Normal human B cells were cultured with various dilutions of 
2BH supernatant or conventional growth factor. Proliferation, as measured by tritiated  thymidine 
incorporation, was assayed 3 d after addition of the supernatants. O, T-T hybrid 2Bu supernatant; 
O, conventional growth factor. (B) Comparison of the effects of 2Btl  supernatant and conventional 
[L-2 on proliferation of cytotoxic T  cells. CT6 T  cells  (I X  104 ceils/well in 0.2  m[ volume in flat- 
bottomed microtiter plates) were cultured for 24 h in the presence of various dilutions of hybridoma 
supernatant or supernatant from phytohemagglutin-stimulated PBL. Cells were pulsed with 1 ~Ci 
of tritiated thymidine for 16 h before harvest. 0, T-T hybrid 2Bn supernatant; O, IL-2 standard. 
To determine the molecular weight of the BCGF, concentrated  supernatant  from 
hybrid 2Bn  was applied  to a  gel filtration  column  (G-100 Sephadex).  The column 
was eluted, and 2.5-ml fractions were collected and assayed for the capacity to support 
the proliferation of normal human B cells  (19).  As shown in  Fig.  3,  the majority of 
protein  eluted  before  fraction  55.  Another  peak of optical  density  was  evident  in 
fractions 58-64.  BCGF activity was confined to this peak that had an apparent  18- 
20,000 mol wt. 
Discussion 
The present study reports the successful development of a human T-T cell hybrid- 
oma continuously secreting BCGF.  Enhancement  of human B cell proliferation was 
significantly increased by supernatant from clone 2Bn as compared with convention- j.  L.  BUTLER,  A.  MURAGUCHI,  H.  C.  LANE,  AND  A.  S.  FAUCI  65 
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Flo.  3.  Gel chromatography of 2Bu supernatant. Hybridoma supernatant was concentrated by 
Amicon filtration and fractionated on a Sephadex G-100 column. 2.5-ml fractions were eluted from 
the column and tested for their ability to support B cell proliferation with the results expressed as 
cpm of tritiated  thymidine incorporation  (0).  Arrows indicate the elution profile of the proteins 
used for column calibration.  Protein  concentration of applied  supernatant is represented by the 
absorbance of 280 nm (O). 
ally prepared BCGF.  In  addition,  the  hybridoma supernatant  was  far superior to 
conventionally  prepared  BCGF  in  maintaining  B  cell  proliferation  in  long-term 
cultures. 
To optimize the conditions for cell hybridization, we attempted to obtain highly 
purified normal  human  peripheral  blood T  lymphocytes. An  efficient enrichment 
procedure was  found in  the two-step method of rosetting with AET-treated sheep 
erythrocytes, followed by passage through a nylon wool column. Earlier experiments 
had shown  a  significant increase in  fusion efficiency when enriched populations of 
human T  cells were activated by mitogen before fusion (J. L. Butler and A. S. Fauci, 
unpublished observations). Therefore, T  cell blasts induced by Con A  were used in 
the fusion experiments. Hybrid growth and subsequent cloning were enhanced by the 
use of media containing 30% FCS, as reported in a previous study (21). 
When the wells from the initial cloning were screened, BCGF activity was identified 
in 17 wells. One well was chosen for recloning because of its rapid growth character- 
istics, while cells in the remaining wells were kept in culture with no further cloning. 
On  subsequent  screening  4  wk  later,  supernatants  from  only  three  of the  wells 
continued to enhance B cell proliferation. This loss of hybrid function could be the 
result of loss  of genes coding for the  production and  secretion of BCGF.  Another 
potential explanation of this phenomenon is overgrowth of the cultures by nonfunc- 
tional hybrids that are better adapted to tissue culture. Thus, it is possible that early, 
aggressive cloning is an important step in preserving function of T  cell hybridomas, 
as has been emphasized in a recent study (3). 
Although  the  activities  of murine  BCGF  and  IL-2  have  been  separated  on  an 
immunochemical  basis  (22),  it  has  not  been  possible to achieve this  separation  of 
human BCGF and IL-2 (A. Muraguchi and A. S. Fauci, unpublished observations). 66  B CELL GROWTH  FACTOR SECRETING HUMAN T-T CELL HYBRIDOMA 
Therefore, it was conceivable that IL-2 was also present in the hybridoma supernatant 
and  could  stimulate  a  few  residual  T  cells  that  might  have  been  present  in  the 
responding B cell populations used in our BCGF assay system. These activated T  cells 
could then support B cell proliferation by the elaboration of soluble growth factors. 
To evaluate this possible mechanism, 2Bll supernatant  was assayed for IL-2 activity 
using an IL-2-dependent T  cell line. No IL-2 activity was found in the supernatant, 
which  indicated  that  the  BCGF  in  the  hybridoma  supernatant  was  separate  and 
distinct  from  IL-2.  Furthermore,  the  hybridoma  supernatant  did  not  induce  the 
differentiation  of  B  cells  to  secrete  immunoglobulin,  an  activity  that  has  been 
identified with T  cell-replacing factor (23-25). 
The availability of purified BCGF in virtually unlimited quantities, which supports 
the  proliferation  of normal  human  B  cells  and  which  is  devoid  of IL-2 or T  cell- 
replacing activity, should prove of extreme value in the precise biochemical charac- 
terization of human BCGF as well as in studies aimed at the long-term growth and 
cloning of normal human B cells. Finally, future development of panels of human T 
cell hybridomas with a  range of distinct  functional  capabilities will make available 
important sources of purified factors with which to explore the mechanisms of human 
immunoregulation. 
Summary 
The success of long-term culture  of normal  human  and  murine  B  cells has been 
hampered  by  the  limited  availability  of  soluble  factors  capable  of  maintaining 
proliferation of activated B lymphocytes. Previous experiments using various culture- 
derived supernatants  in a  human system were unable to separate the activities of B 
cell growth factor (BCGF) and interleukin 2 (IL-2) by immunochemical means. Thus, 
purified  factors with  BCGF activity in  the  absence of IL-2 activity have not  been 
available for study. In the present study, normal human peripheral blood T  cells were 
fused  with  the  hypoxanthine/aminopterin/thymidine-sensitive  human  T-leukemic 
cell  line,  CEM-6.  Supernatants  from the  resulting  hybrid cells  were  tested  for the 
ability to maintain proliferation of normal human B cells in a recently described assay 
system  for  human  BCGF.  Hybrids  demonstrating  BCGF  activity  were  cloned  by 
limiting dilution. One hybrid clone, 2Bn, continued to support proliferation of B cells 
in both long-term cultures and 6-d assays at a level significantly above that seen with 
conventionally produced growth factors. No IL-2 activity was found in the superna- 
tant from hybrid 2Bll. The hybridoma supernatant was fractionated by gel filtration, 
and maximum proliferation of B cells was supported by the 18-20,000 mol wt protein 
fraction. Thus, a  human T-T cell hybridoma that has BCGF activity in the absence 
of any demonstrable IL-2 activity has been developed. Human T-T cell hybridomas 
secreting  discrete  immunoregulatory  factors  should  prove  to  be  powerful  tools  in 
dissecting the mechanisms of immunoregulation of human lymphocyte function. 
Received  for publication 9June 1982. 
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